17.25
+0.03(+0.17%)
Currency In USD
Sector
Healthcare
Industry
Biotechnology
Employees
49
First IPO Date
May 18, 2021
| Name | Title | Pay | Year Born |
| Dr. Riad Sherif M.B.A., M.D. | Chief Executive Officer & Director | 0 | 1968 |
| Ms. Rebecca Weil | Chief Commercial Officer | 0 | N/A |
| Dr. Sharon Klier M.D., M.P.H. | Chief Development Officer | 0 | N/A |
| Dr. Snehal Shah Pharm.D. | President of Research & Development | 0 | N/A |
| Ms. Sylvia Cheung | Chief Financial Officer | 0 | 1975 |
| Ms. Gudrun Bachmann Ph.D. | Chief Technology Officer | 0 | N/A |
| Ms. Virginia R. Dean | Chief Human Resources Officer | 0 | 1967 |
| Mr. Daniel S. Char J.D. | Chief Legal Officer | 0 | 1961 |
| Mr. Páll Ragnar Jóhannesson | Chief Business Officer | 0 | 1982 |
| Dr. Ramin Tadayoni M.D., Ph.D. | Chief Scientific Officer | 0 | N/A |
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.